The potential role of ERβ isoforms in the clinical management of breast cancer

Histopathology

Volumn 53, Issue 4, 2008, Pages 374-380

  Green, C A ^b   Peter, M B ^b   Speirs, V ^b   Shaaban, A M ^a,b  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; ER beta isoforms; Oestrogen receptors; Prognosis; Tamoxifen

Indexed keywords

21 (4 DIETHYLAMINOMETHYL 2 METHOXYPHENOXY) 7ALPHA METHYL 19 NORPREGNA 1,3,5(10) TRIEN 3 OL; ANTINEOPLASTIC AGENT; ERB 41; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA SELECTIVE AGONIST; MESSENGER RNA; PROGESTERONE RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PREVENTION; DRUG TARGETING; GENE EXPRESSION; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; MODELS, GENETIC; PROTEIN ISOFORMS; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 52649125615     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.02968.x     Document Type: Review

References (51)

1. Green S, Walter P, Kumar V et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986 320 134 139.
2. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996 392 49 53.
3. Ogawa S, Inoue S, Watanabe T et al. Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of estrogen action in human. Nucleic Acids Res. 1998 26 3505 3512.
4. Moore JT, McKee DD, Slentz-Kesler K et al. Cloning and characterization of human estrogen receptor [beta] isoforms. Biochem. Biophys. Res. Comm. 1998 247 75 78.
5. Poola I, Abraham J, Baldwin K, Saunders A, Bhatnagar R. Estrogen receptors beta4 and beta5 are full length functionally distinct ERbeta isoforms: cloning from human ovary and functional characterization. Endocrine 2005 27 227 238.
6. Chi A, Chen X, Chirala M, Younes M. Differential expression of estrogen receptor beta isoforms in human breast cancer tissue. Anticancer Res. 2003 23 211 216.
7. Wurtz JM, Bourguet W, Renaud JP et al. A canonical structure for the ligand-binding domain of nuclear receptors. [erratum appears in Nat Struct Biol. 1996; 3; 206; PMID: 8564548]. Nat. Struct. Biol. 1996 3 87 94.
8. Henttu PM, Kalkhoven E, Parker MG. AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors. Mol. Cell. Biol. 1997 17 1832 1839.
9. Pettersson K, Delaunay F, Gustafsson JA. Estrogen receptor beta acts as a dominant regulator of estrogen signaling. Oncogene 2000 19 4970 4978.
10. Zhao C, Matthews J, Tujague M et al. Estrogen Receptor [beta]2 Negatively Regulates the Transactivation of Estrogen Receptor [alpha] in Human Breast Cancer Cells. Cancer Res. 2007 67 3955 3962.
11. Leung YK, Mak P, Hassan S, Ho SM. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc. Natl. Acad. Sci. U.S.A. 2006 103 13162 13167.
12. Hall JM, McDonnell DP. Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol. Intervent. 2005 5 343 357 Review C, Toresson G, Xu L, Koehler KF, Gustafsson JA, hlman-Wright K. Mouse estrogen receptor beta isoforms exhibit differences in ligand selectivity and coactivator recruitment. Biochemistry 2005 44 7936 7944.
13. Taylor AH, al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues. J. Mol. Endocrinol. 2000 24 145 155.
14. Skliris GP, Munot K, Bell SM et al. Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J. Pathol. 2003 201 213 220.
15. Shaaban AM, O'Neill PA, Davies MP et al. Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am. J. Surg. Pathol. 2003 27 1502 1512.
16. Park BW, Kim KS, Heo MK et al. Expression of estrogen receptor-beta in normal mammary and tumor tissues: is it protective in breast carcinogenesis? Breast Cancer Res. Treat. 2003 80 79 85.
17. Speirs V, Skliris GP, Burdall SE, Carder PJ. Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J. Clin. Pathol. 2002 55 371 374.
18. Weitsman GE, Skliris G, Ung K et al. Assessment of multiple different estrogen receptor-beta antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions. Breast Cancer Res. Treat. 2006 100 23 31.
19. O'Neill PA, Davies MP, Shaaban AM et al. Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers. Br. J. Cancer 2004 91 1694 1702.
20. Leygue E, Dotzlaw H, Watson PH, Murphy LC. Expression of estrogen receptor beta1, beta2, and beta5 messenger RNAs in human breast tissue. Cancer Res. 1999 59 1175 1179.
21. Davies MP, O'Neill PA, Innes H et al. Correlation of mRNA for oestrogen receptor beta splice variants ERbeta1, ERbeta2/ERbetacx and ERbeta5 with outcome in endocrine-treated breast cancer. J. Mol. Endocrinol. 2004 33 773 782.
22. Park BW, Kim KS, Heo MK et al. The changes of estrogen receptor-beta variants expression in breast carcinogenesis: decrease of estrogen receptor-beta2 expression is the key event in breast cancer development. J. Surg. Oncol. 2006 93 504 510.
23. Omoto Y, Kobayashi S, Inoue S et al. Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur. J. Cancer 2002 38 380 386.
24. Palmieri C, Lam EW, Mansi J et al. The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res 2004 10 2421 2428.
25. Saji S, Omoto Y, Shimizu C et al. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Cancer Res. 2002 62 4849 4853.
26. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 2001 61 2537 2541.
27. Esslimani-Sahla M, Kramar A, Simony-Lafontaine J, Warner M, Gustafsson JA, Rochefort H. Increased estrogen receptor [beta]cx expression during mammary carcinogenesis. Clin. Cancer Res. 2005 11 3170 3174.
28. Shaaban AM, Green AR, Karthik S et al. The prognostic significance of ER1, -2 and -5 expression in breast cancer. BCRT 2006 100 s10. 2006. SABCS abstract.
29. Mandusic V, Nikolic-Vukosavljevic D, Tanic N et al. Expression of estrogen receptor beta wt isoform (ERbeta1) and ERbetaDelta5 splice variant mRNAs in sporadic breast cancer. J. Cancer Res. Clin. Oncol. 2007 133 571 579.
30. Vinayagam R, Sibson DR, Holcombe C, Aachi V, Davies M. Association of oestrogen receptor beta 2 (ERbeta2/ERbetacx) with outcome of adjuvant endocrine treatment for primary breast cancer - a retrospective study. BMC Cancer 2007 7 131.
31. Inoue S, Ogawa S, Horie K et al. An estrogen receptor beta isoform that lacks exon 5 has dominant negative activity on both ERalpha and ERbeta. Biochem. Biophys. Res. Comm. 2000 279 814 819.
32. Shaw JA, Udokang K, Mosquera JM, Chauhan H, Jones JL, Walker RA. Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas. J. Pathol. 2002 198 450 457.
33. Poola I, Fuqua SA, De Witty RL, Abraham J, Marshallack JJ, Liu A. Estrogen receptor alpha-negative breast cancer tissues express significant levels of estrogen-independent transcription factors, ERbeta1 and ERbeta5: potential molecular targets for chemoprevention. Clin. Cancer Res. 2005 11 7579 7585.
34. Skliris GP, Leygue E, Curtis-Snell L, Watson PH, Murphy LC. Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br. J. Cancer 2006 95 616 626.
35. Gruvberger-Saal SK, Bendahl PO, Saal LH et al. Estrogen receptor [beta] expression is associated with tamoxifen response in er[alpha]-negative breast carcinoma. Clin. Cancer Res. 2007 13 1987 1994.
36. Fleming FJ, Hill AD, McDermott EW, O'higgins NJ, Young LS. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer. J. Clin. Endocrinol. Metab. 2004 89 375 383.
37. Esslimani-Sahla M, Simony-Lafontaine J, Kramar A et al. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin. Cancer Res. 2004 10 5769 5776.
38. McGuire WL. Current status of estrogen receptors in human breast cancer. Cancer 1975 36 638 644.
39. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992 339 1 15.
40. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998 351 1451 1467.
41. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 1998 11 155 168 Review PJ, Murphy CE, Dervan P et al. A multi-centre investigation towards reaching a consensus on the immunohistochemical detection of ERbeta in archival formalin-fixed paraffin embedded human breast tissue. Breast Cancer Res. Treat. 2005 92 287 293.
42. Treeck O, Pfeiler G, Horn F et al. Novel estrogen receptor beta transcript variants identified in human breast cancer cells affect cell growth and apoptosis of COS-1 cells. Mol. Cell. Endocrinol. 2007 29 264(1-2): 50 60.
43. Murphy LC, Peng B, Lewis A et al. Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J. Mol. Endocrinol. 2005 34 553 566.
44. Treeck O, Pfeiler G, Mitter D, Lattrich C, Piendl G, Ortmann O. Estrogen receptor [beta]1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J. Endocrinol. 2007 193 421 433.
45. Kelloff GJ, Lippman SM, Dannenberg AJ et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - a plan to move forward. Clin. Cancer Res. 2006 12 3661 3697 Review MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J. Med. Chem. 2001 44 4230 4251.
46. Malamas MS, Manas ES, McDevitt RE et al. Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J. Med. Chem. 2004 47 5021 5040.
47. Yamamoto Y, Shibata J, Yonekura K et al. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor [alpha] and a partial agonist on estrogen receptor [beta] with low uterotrophic effect. Clin. Cancer Res. 2005 11 315 322.
48. Blakely LJ, Buzdar A, Chang HY et al. A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer. Clin. Cancer Res. 2004 10 5425 5431.
49. Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L et al. Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine. J. Transl. Med. 2006 4 32.
50. Papadaki I, Mylona E, Giannopoulou I, Markaki S, Keramopoulos A, Nakopoulou L. PPARgamma expression in breast cancer: clinical value and correlation with ERbeta. Histopathology 2005 46 37 42.
51. Nakopoulou L, Lazaris AC, Panayotopoulou EG et al. The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J. Clin. Pathol. 2004 57 523 528.